Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using our proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Our focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept we call “chemoprotection."

More >>

Stock

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

WATERTOWN, Mass. , June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron al...
- - - Observed a protective effect against severe chemotherapy-induced anemia and thrombocytopenia across all dose levels - - - Management to host a conference call and webcast today at 8:30 a.m. EDT ...
WATERTOWN, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical ...

Upcoming Events

More events are coming soon.

Investor Contacts

Rick Wanstall

Chief Financial Officer and Treasurer

rwanstall@aileronrx.com

LifeSci Advisors, LLC.

Hans C. Vitzthum

617-535-7743

hans@lifesciadvisors.com